Ysios Capital backs €45m series-C for Xeltis

The round was led by an anonymous strategic investor and also included contributions from existing investors Life Sciences Partners (LSP), Kurma Partners and VI Partners.

The fresh capital will be used to continue clinical development and accelerate market development.

It is the largest investment round for a private medical device company in Europe since 2015, when Woodford and Arthurian Life Sciences led a $100m series-C for Swiss insulin infusion device developer Cequr, according to unquote" data.

Previous funding
LSP and Kurma led a €27m series-A for Xeltis in December 2013. VI Partners was already a shareholder at this stage and also took part in the financing.

All three investors also backed the company's €3m series-B in December 2015.

Company
Established in 2006, Xeltis develops synthetic biodegradable heart valves and blood vessels, enabling a completely new therapeutic category called endogenous tissue growth. It is at the clinical stage and has released data showing fully functional valves in vivo. The company was founded in Zurich but is now headquartered in Eindhoven.

People
Xeltis – Laurent Grandidier (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• Healthcare
• Benelux
• Switzerland
• Venture
• Life Science Partners